Last reviewed · How we verify

NCT03074513

Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors

Active, enrolled Phase 2 Last updated 11 March 2026
What this trial tests

Phase 2 trial testing Atezolizumab in Appendix Adenocarcinoma in 133 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
3 March 2017
Primary endpoint
30 September 2027
30 September 2027

Quick facts

Lead sponsorM.D. Anderson Cancer Center
PhasePhase 2
StatusActive, enrolled
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment133
Start date3 March 2017
Primary completion30 September 2027
Estimated completion30 September 2027
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

18 and older, any sex, with Appendix Adenocarcinoma or Human Papillomavirus-Related Anal Squamous Cell Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This phase II trial studies how well atezolizumab and bevacizumab work in treating patients with rare solid tumors. Immunotherapy with monoclonal antibodies, such as atezolizumab and bevacizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Targeting Tumor Microenvironment for Cancer Therapy.
    Roma-Rodrigues C, Mendes R, Baptista PV, Fernandes AR. · · 2019 · cited 865× · PMID 30781344 · DOI 10.3390/ijms20040840
  2. Cervical Cancer Immunotherapy: Facts and Hopes.
    Ferrall L, Lin KY, Roden RBS, Hung CF, et al · · 2021 · cited 255× · PMID 33888488 · DOI 10.1158/1078-0432.ccr-20-2833
  3. Tumor microenvironment: an evil nexus promoting aggressive head and neck squamous cell carcinoma and avenue for targeted therapy.
    Bhat AA, Yousuf P, Wani NA, Rizwan A, et al · · 2021 · cited 119× · PMID 33436555 · DOI 10.1038/s41392-020-00419-w
  4. Immune Modulation of Head and Neck Squamous Cell Carcinoma and the Tumor Microenvironment by Conventional Therapeutics.
    Miyauchi S, Kim SS, Pang J, Gold KA, et al · · 2019 · cited 107× · PMID 30814108 · DOI 10.1158/1078-0432.ccr-18-0871
  5. Tumor Vasculatures: A New Target for Cancer Immunotherapy.
    Liu Z, Wang Y, Huang Y, Kim BYS, et al · · 2019 · cited 88× · PMID 31331639 · DOI 10.1016/j.tips.2019.07.001
  6. Optimized antiangiogenic reprogramming of the tumor microenvironment potentiates CD40 immunotherapy.
    Kashyap AS, Schmittnaegel M, Rigamonti N, Pais-Ferreira D, et al · · 2020 · cited 71× · PMID 31889004 · DOI 10.1073/pnas.1902145116
  7. Improving antitumor immunity using antiangiogenic agents: Mechanistic insights, current progress, and clinical challenges.
    Li SJ, Chen JX, Sun ZJ. · · 2021 · cited 63× · PMID 34137513 · DOI 10.1002/cac2.12183
  8. Current status and advances of immunotherapy in nasopharyngeal carcinoma.
    Xu JY, Wei XL, Wang YQ, Wang FH. · · 2022 · cited 62× · PMID 35547095 · DOI 10.1177/17588359221096214

Verify or expand the search:

Other trials of Atezolizumab

Trials testing the same drug.

Other M.D. Anderson Cancer Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03074513.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing